Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.

J Transl Med · 2025 · PMC11969774 · PMID 40181350

Europe PMC DOI

hedged sentence

0.0860

closest p · 1.7× alpha

0.0860

boldest claim

The sentences

a nonsignificant trendP = 0.086so close (0.05 < p ≤ 0.1)

In our study, there was a nonsignificant trend toward lower 2-year PFS rates in MRD-positive patients compared to MRD-negative patients ( P = 0.086), reinforcing the role of MRD status as a key prognostic factor [ 30 , 31 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.